Welcome to our dedicated page for Alpha Teknova SEC filings (Ticker: TKNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alpha Teknova, Inc. filings document the company’s operating results, governance matters and public-company disclosures as a producer of critical reagents for life-sciences customers. Form 8-K reports furnish quarterly and annual earnings releases, revenue by Lab Essentials and Clinical Solutions, guidance, cash metrics, borrowings and related exhibits.
Proxy and current-report filings cover director elections, auditor ratification, annual meeting vote results, board and stockholder procedures, and amendments to the company’s Code of Business Conduct and Ethics. The filing record also identifies Teknova’s common-stock issuer status, emerging growth company disclosure and corporate-governance framework.
Alpha Teknova, Inc. President and CEO Stephen Gunstream reported two equity transactions. On March 6, 2026, he made an open-market purchase of 26,000 shares of common stock at a weighted average price of $2.1462 per share, bringing his direct common stock holdings to 269,497 shares. Separately, on February 15, 2026, he received a grant of 429,000 non-qualified stock options with an exercise price of $0.00 per option. These options vest in 48 equal monthly installments on the same day of each month following the February 15, 2026 grant date.
Alpha Teknova, Inc. is a specialist manufacturer of custom reagents used in developing novel therapies, vaccines, and molecular diagnostics for more than 3,000 life science customers. It focuses on fast, made‑to‑order production from discovery through commercialization, with most products made in Hollister, California.
The company organizes its portfolio into Lab Essentials and Clinical Solutions. In 2025, Lab Essentials contributed 76.6% of revenue, largely from catalog items, while higher‑value Clinical Solutions contributed 18.9%, mostly custom GMP‑grade products. About 24% of revenue came from cell and gene therapy customers, a key long‑term growth focus.
Teknova reported a 2025 net loss of $17.3 million, an improvement from a $26.7 million net loss in 2024, while continuing to invest in capacity, automation, and quality systems. The business highlights high customer loyalty, with roughly 95% annual retention among larger accounts, rapid lead times for custom products, and strong exposure to growing markets like mRNA, molecular diagnostics, and genomics, balanced by risks around funding cycles, competition, supply chain concentration, and regulatory demands.
Alpha Teknova, Inc. reported moderate growth and much stronger margins for 2025 while remaining unprofitable. Total revenue for 2025 was $40.5 million, up 7% from $37.7 million, with fourth-quarter revenue of $10.0 million, up 8% year over year.
Full-year gross margin improved to 33.2% from 19.2%, helped by higher revenue and manufacturing efficiency gains, and operating expenses fell to $30.4 million from $33.4 million. Net loss narrowed to $17.3 million (negative $0.32 per share) from $26.7 million, and Adjusted EBITDA improved to negative $6.7 million from negative $14.5 million.
Free Cash Flow for 2025 was negative $9.8 million, better than negative $13.5 million in 2024 and ahead of the company’s prior target. Teknova ended 2025 with $21.3 million in cash and short-term investments and $13.2 million of gross debt, and guided 2026 revenue to $42–44 million with expected Free Cash Outflow of less than $10 million.
Alpha Teknova (TKNO) reported Q3 2025 results. Revenue was $10.5 million, up 9.2% year over year. Gross margin improved to 30.7% from 0.9% a year ago, reflecting the absence of prior-year inventory charges. Operating loss narrowed to $4.0 million, and net loss was $4.3 million (net loss per share of $0.08).
For the first nine months, revenue reached $30.5 million (up 7.2%) with a 33.4% gross margin. General and administrative costs fell year over year, contributing to a smaller operating loss. Cash and cash equivalents plus short‑term investments totaled $22.1 million as of September 30, 2025, within $29.6 million of net working capital.
The company’s amended credit facility totals $28.245 million (term loan and revolver) and includes covenants, including a minimum trailing‑twelve‑month net revenue of $39.0 million for the period ending December 31, 2025, and a minimum cash requirement of $8.0 million. Shares outstanding were 53,529,174 as of November 5, 2025.
Alpha Teknova (TKNO) furnished Q3 results. The company reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The release was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01, with the full text included as Exhibit 99.1.
The materials are designated as furnished, not filed, under the Exchange Act.
Alpha Teknova, Inc. reported revenue of $10.3 million for the quarter ended June 30, 2025, up 7.0% from the prior-year quarter, and $20.1 million for the six months ended June 30, 2025, up 6.2% year-over-year. Gross profit improved materially, with gross margin rising to 38.7% for the quarter (from 29.2%) and to 34.8% for the six months (from 26.5%), driven by stated manufacturing efficiency gains and higher revenue.
The company recorded a net loss of $3.6 million in the quarter and $8.2 million for the six-month period; net loss per share was $0.07 and $0.15, respectively. Balance sheet highlights include total assets of $110.5 million, cash of $3.3 million and short-term held-to-maturity investments of $20.7 million (combined $24.0 million), long-term debt, net of $13.0 million, and stockholders' equity of $76.1 million. The company reports $31.6 million in net working capital.
Liquidity is supported by a $28.245 million credit facility (a $23.245 million term loan and a $5.0 million revolver) that matures in 2030; the facility includes a $39.0 million trailing 12-month minimum net revenue covenant and an $8.0 million minimum cash covenant. Notable concentrations disclosed include Distributor customer A representing 22% of revenue for the quarter and a distributor supplier representing 26% of inventory purchases. The filing shows progress on margin improvement and cost control but the company remains unprofitable with existing debt and concentration risks.